DNLI Q3 2025 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$137M

Net Income

-$127M

EPS (Diluted)

$-0.74

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$106M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$129M

Stockholders' Equity

$926M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$137M	-$123M	-11.6%
Net Income	-$127M	-$107M	-18.4%